CV Shariat_AKH - Vienna OMI

iochemical progression after radical prostatectomy.• “Best Poster” in diagnosis and staging of urothelial tumours II 200823rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008.Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.• “Best Poster” in Prostate Cancer: Staging (I) 2008American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008.Improved prediction of disease relapse after radical prostatectomy using a panel ofpreoperative blood-based biomarkers.• “Best Poster” in Prostate Cancer: Advanced (I) 2008American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008.J.Urol 179(4): 186, 2008. The effect of androgen deprivation therapy on the rate ofsubsequent non-cancer morbidities.• “Best Poster” in Urothelial Cancer: Surgical Therapy 2008American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008.More extensive lymphadenectomy improves the prognosis of patients with upper tracturothelial carcinoma without nodal metastases.• Reviewer of the month January – European Urology 2008• ASCO Cancer Foundation Merit Award 2008American Society of Clinical Oncology Cancer Foundation and the ASCO/National CancerInstitute/EORTC Scientific Committee, Annual Meeting on Molecular Markers in Cancer,Hollywood, FL.• Listed in the “Guide to America’s Top Urologists 2008” 2008• Best Poster 2008Society of Urologic Oncology Annual Meeting, National Cancer Institute,December 4-6th, 2008, National Institutes of Health, Bethesda, MD. Multi-institutionalvalidation of the predictive value of Ki-67 labeling index in patients with bladder cancer.• Merit Award 2009ASCO Cancer Foundation Board of Directors and the 2009 Genitourinary CancersSymposiumProgram Committee, Genitourinary Cancers Symposium in Orlando, FL.Use of pre-treatment biomarker levels to improve the accuracy of post-prostatectomynomogram for prediction of biochemical recurrence• “Best Poster” in Transitional Cell Carcinoma Pathology 200924th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21,2009. Predictive value of the combination of immunohistochemical markers in patientswith pT1 disease at radical cystectomy.• “Best Poster” in Management of Advanced Urothelial Pathology 200924th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21,2009.Improved prediction of clinical outcomes in patients with advanced bladder cancer using apanel of four cell cycle regulators.• “Best Poster” in Upper and Lower Urinary Tract Carcinoma 200924th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009.Proposal for subclassification of pT3 urothelial cancer of the renal pelvis.• First Prize for the Best Abstract 200925th European Association of Urology Annual Meeting, Barcelona, Spain. April 16-20,2010. Her2 expression status provides independent prognostic information in patientswith urothelial carcinoma of the bladder: a rationale for targeted therapy.• “Best Poster” in Urothelial Cancer: Natural history and pathophysiology/markers 2010American Urological Association Annual Meeting, San Francisco, CA,www.vienna-omi.at 28.08.2013